Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher C Parker

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
BJU International|November 6, 2009
The relevance of a hypoxic tumour microenvironment in prostate cancerGrant D Stewart, James A Ross, Duncan B McLaren, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 15, 2017
The potential of <sup>223</sup>Ra and <sup>18</sup>F-fluoride imaging to predict bone lesion response to treatment with <sup>223</sup>Ra-dichloride in castration-resistant prostate cancerIain Murray, Sarah J Chittenden, Ana M Denis-Bacelar, et al.
Clinical and Translational Radiation Oncology|September 15, 2021
Time management: Improving the timing of post-prostatectomy radiotherapy, clinical trials, and knowledge translationKai Yun Ooi, Ian Pereira, Himanshu Nagar, et al.
BJU International|February 14, 2006
Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancerVedang Murthy, Andrew R Norman, Mehdi Shahidi, et al.
European Urology Oncology|May 18, 2019
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate CancerAmar U Kishan, Rahul D Tendulkar, Phuoc T Tran, et al.
European Urology|February 5, 2014
Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic reviewRoderick C N van den Bergh, Hashim U Ahmed, Chris H Bangma, et al.
European Urology|September 25, 2012
A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancerChristopher C Parker, Sarah Pascoe, Aleš Chodacki, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 27, 2007
Outcome of early detection and radiotherapy for occult spinal cord compressionRamachandran Venkitaraman, Yolanda Barbachano, David P Dearnaley, et al.
European Radiology|August 24, 2023
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastasesRicardo Donners, Nina Tunariu, Holly Tovey, et al.
European Urology|March 18, 2008
Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillanceNicholas J van As, Andrew R Norman, Karen Thomas, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
BJU International|November 6, 2009
The relevance of a hypoxic tumour microenvironment in prostate cancerGrant D Stewart, James A Ross, Duncan B McLaren, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 15, 2017
The potential of <sup>223</sup>Ra and <sup>18</sup>F-fluoride imaging to predict bone lesion response to treatment with <sup>223</sup>Ra-dichloride in castration-resistant prostate cancerIain Murray, Sarah J Chittenden, Ana M Denis-Bacelar, et al.
Clinical and Translational Radiation Oncology|September 15, 2021
Time management: Improving the timing of post-prostatectomy radiotherapy, clinical trials, and knowledge translationKai Yun Ooi, Ian Pereira, Himanshu Nagar, et al.
BJU International|February 14, 2006
Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancerVedang Murthy, Andrew R Norman, Mehdi Shahidi, et al.
European Urology Oncology|May 18, 2019
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate CancerAmar U Kishan, Rahul D Tendulkar, Phuoc T Tran, et al.
European Urology|February 5, 2014
Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic reviewRoderick C N van den Bergh, Hashim U Ahmed, Chris H Bangma, et al.
European Urology|September 25, 2012
A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancerChristopher C Parker, Sarah Pascoe, Aleš Chodacki, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 27, 2007
Outcome of early detection and radiotherapy for occult spinal cord compressionRamachandran Venkitaraman, Yolanda Barbachano, David P Dearnaley, et al.
European Radiology|August 24, 2023
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastasesRicardo Donners, Nina Tunariu, Holly Tovey, et al.
European Urology|March 18, 2008
Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillanceNicholas J van As, Andrew R Norman, Karen Thomas, et al.
Pageof 6